Mukka Proteins plans to raise Rs 47 crore by issuing 2 crore convertible warrants at Rs 23.50 each to non-promoter entities for working capital and expansion.

Mukka Proteins Plans Rs 47 Crore Capital Infusion via Warrants

Mukka Proteins will raise up to Rs 47 crore by issuing 2 crore convertible warrants at Rs 23.50 per warrant.

Reader Takeaway: Growth funding secured, but future dilution is a watch point for shareholders.

What just happened

Mukka Proteins Limited announced plans to raise approximately Rs 47 crore by issuing 2 crore convertible warrants to non-promoter entities. Each warrant is priced at Rs 23.50, with 25% of the amount payable upfront and the remaining 75% due upon conversion into equity shares within 18 months.

Why this matters

This capital infusion is intended to strengthen the company's working capital and fund its business expansion plans. The board views this preferential issue as an efficient way to secure funds for growth initiatives. Upon full conversion, the promoter group's shareholding is expected to decrease from 73.33% to 68.75%, while public shareholding will increase.

The backstory

Mukka Proteins, a manufacturer of animal feed, has recently gone public. This move to raise additional capital shortly after its listing indicates a focus on aggressive growth and operational scaling.

What changes now

The issuance of warrants creates a pathway for future equity dilution. The company will receive initial funds from warrant subscribers, and if all warrants are converted, the total outstanding shares will increase.

Risks to watch

The primary concern for existing shareholders is potential equity dilution. Additionally, there's a risk that the allottees may not exercise their conversion option within the 18-month window, leading to forfeiture of initial payments. Investors need to monitor the effective deployment of these funds and the eventual conversion rate.

Peer comparison

Companies in the animal feed sector often seek capital for expansion and to enhance product offerings. This warrant issuance is a strategic move to fund such growth objectives, aligning with industry practices for scaling operations.

Context metrics (time-bound)

The cut-off date for determining voting rights on this issue is June 10, 2026. E-voting will commence on June 13, 2026, and conclude on July 12, 2026. The conversion window for the warrants is 18 months from the allotment date.

What to track next

Investors should closely track the shareholder voting outcomes, the actual exercise of warrants by the allottees, and how effectively the company utilizes the raised capital for its stated expansion and working capital needs.